Chinese biopharmaceutical company Mabwell (SHA:688062) announced on Thursday that the first patient has been dosed in a US clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumours.

The Phase I/II study is the first-in-human study of the product in the United States. The study aims to evaluate the safety, pharmacokinetics and efficacy in patients with advanced colorectal cancer and other advanced gastrointestinal tumours. Previously, 7MW4911 received clinical trial approval and completed first patient dosing in China.

7MW4911 is a novel CDH17-targeting ADC developed by Mabwell based on its proprietary IDDC platform. It is composed of a highly specific CDH17 monoclonal antibody capable of efficient internalisation into tumour cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.